报告期内，公司依托产品竞争力提升与营销体系优化升级的共同驱动，经营规模稳步扩大，业务结构持 续改善，整体发展态势稳健向好。研发创新层面，公司坚持以研发创新驱动业务增长，报告期内持续巩 固在磁刺激、电生理、电刺激等领域的技术领先优势，并加速激光、射频等能量源技术的产业化落地， 全线产品市场竞争力显著增强。其中，核心产品矩阵表现亮眼，经颅磁刺激仪、团体生物反馈仪、盆底 射频机器人及配套耗材等主力品种销量实现较快增长，市场渗透率稳步提升，终端反馈积极向好。市场 营销层面，公司深化营销体系改革，渠道网络建设全面提速，新客户拓展效率与终端覆盖度同步提升； 受益于康复医疗市场需求持续释放，精神康复、盆底康复、神经康复三大业务板块协同发力，共同驱动 销售业绩稳健提升。展望后续，公司将继续强化核心产品竞争力，完善国内外渠道建设，加快海外注册 准入，并推行精益生产管理，依托康复业务与新兴板块的协同发展，推动经营业绩保持稳健、可持续的 增长态势。 格隆汇2月26日丨伟思医疗(688580.SH)公布2025年度业绩快报，本报告期，公司实现营业总收入4.63亿 元，同比增加15.66%；营业利润1.51亿元，同比增加 35.03% ...

作为省级重点中医专科，老年病科以专业实力筑牢老年健康根基。引进老年综合评估系统，多维度精准 定位患者健康问题，结合中医"杂合以治"理念，制定个性化方案；针对老年特有病症，科室善用经方汤 剂、益元膏等中药剂型，搭配耳部三联治疗等外治疗法，实现内服外治协同增效；配备经颅磁刺激仪、 平衡功能训练系统等先进设备，形成"中医辨证+现代康复"的双重保障，让传统医学在老年诊疗中焕发 新生，为老年特有病症提供针对性解决方案。 下一步，该院老年病科将以此次获评作为新起点，持续深耕中医特色优势，优化适老化服务细节，拓展 医养结合服务边界。以精湛的诊疗技术、便捷的服务流程、暖心的人文关怀，践行老年友善服务理念， 守护每一位老年人的健康与尊严。 本报讯 记者徐婕报道 近日，在云南省开展的2025年度老年友善医疗机构建设工作中，经多轮严格审 核，昆明市中医医院获评"2025年度老年友善医疗机构"。 针对老年患者就医的 "急难愁盼"，该院从流程、环境、保障多维度推进适老化改造。为80岁及以上老 年患者开通"银发绿色通道"，减免挂号诊查费并优先诊疗，大大缩短就医时长；门诊大厅一站式服务中 心整合全流程服务，自助缴费机与人工挂号、现金支付方 ...

Core Viewpoint - Weisi Medical emphasizes its commitment to research and innovation as the driving force behind its competitive advantage in the rehabilitation medical device sector [1] Group 1: Company Overview - Weisi Medical is a technology-driven enterprise in the domestic rehabilitation medical device field, focusing on continuous R&D investment and precise market positioning [1] - The company has established significant competitive advantages in various niche markets, maintaining excellent profitability and market share [1] Group 2: Product Coverage and Market Position - The company's products cover a wide range of domestic medical institutions, including general hospitals, obstetrics, psychiatry, pediatrics, and rehabilitation specialty hospitals [1] - In key niche markets such as pelvic and postpartum rehabilitation, mental health, and pediatric rehabilitation, Weisi Medical ranks among the top domestic manufacturers [1] - Core products like transcranial magnetic stimulators, pelvic magnetic stimulators, and group biofeedback devices are leading in market sales compared to similar products [1] Group 3: Future Strategy - Looking ahead, the company plans to strengthen its R&D engine, accelerate the localization of high-end equipment, and deepen the layout of rehabilitation clinical solutions [1] - The goal is to consolidate its position as a technology leader in the industry and to drive the overall upgrade of China's rehabilitation medical industry [1]

Core Viewpoint - Wuhan Yirui Medical Equipment Technology Co., Ltd. has developed a transcranial magnetic stimulation (TMS) device, which has received the first Class III medical device registration certificate in the field of mental health in China, indicating its approval for use in treating depression [1][2][3]. Company Overview - Wuhan Yirui was established in 2007 and focuses on brain science technology innovation, particularly in magnetic stimulation technology. The company is headquartered in Wuhan and has a professional team for R&D, production, clinical medicine, after-sales service, and training [18]. - The company has over 200 invention patents and has participated in more than 100 research projects, emphasizing its commitment to the industrialization of brain science technology [18]. Product Details - The TMS device is one of the core products of the company, designed to non-invasively stimulate the brain's motor areas to regulate brain function and treat diseases. It features multiple innovative characteristics and technical breakthroughs [4][6]. - The device has received international certifications such as ISO9001 and ISO13485, ensuring product quality and compliance [6]. - It offers various stimulation modes, including single-pulse, double-pulse, and repetitive TMS (rTMS), catering to different clinical needs [6][7]. - The TMS device is applicable for treating a wide range of mental and neurological disorders, including depression, anxiety, insomnia, post-stroke rehabilitation, Alzheimer's disease, chronic pain, and autism [7][12]. Clinical Research - The company has conducted extensive clinical trials in collaboration with several top-tier hospitals across the country, validating the safety and efficacy of the TMS device for treating depression through multi-center randomized controlled trials (RCT) [12][15]. - A nationwide multi-center study on magnetic shock therapy (MST) was initiated to evaluate its efficacy and safety, using the TMS device developed by Yirui [15]. Market Overview - The global market for TMS technology is growing, with the market size in China reaching several hundred million RMB in 2023 and expected to grow from 818 million to 1.595 billion RMB by 2029 [16]. - TMS is recognized as one of the four major brain science technologies of the 21st century, alongside PET, fMRI, and MEG, due to its non-invasive, precise, and safe characteristics [16]. - The company has exported its products to over 10 countries and has a market presence in more than 5,000 medical institutions globally, with over 10,000 units in the domestic market [16][18]. Competitive Landscape - Other major players in the TMS industry include Magventure, Dyansys, Electrocore, Nexstim, Neurosoft, and Cefaly Technology [17].

Core Insights - Brain-computer interface (BCI) technology is transitioning from laboratory research to clinical applications, with significant advancements in treating conditions like paralysis and ALS [1] - The approval of the first Class III medical device registration for transcranial magnetic stimulation (TMS) signifies a shift towards standardized treatment options for depression, enhancing the credibility and adoption of such technologies in clinical settings [2][4] - Chinese companies, particularly Yirui De Group, are leading in the development and commercialization of non-invasive BCI technologies, indicating a strong domestic capability in this emerging field [1][2] Industry Developments - The approval of Class III certification for TMS devices is expected to promote orderly development in the industry, allowing more medical institutions to adopt these technologies for depression treatment [2][4] - The integration of multi-modal data for personalized treatment plans is being pursued, with the aim of creating individualized brain maps for more effective therapy [5] - The inclusion of BCI treatments in health insurance plans at an affordable price point is seen as a catalyst for wider adoption and development of home-use devices [8] Clinical Applications - BCI technology is being utilized in various clinical settings, including enabling paralyzed patients to walk and providing communication aids for ALS patients [6][7] - The development of "neural bypass" techniques through BCI represents a breakthrough in understanding and intervening in neural signal transmission, opening new avenues for treating neurological disorders [7] - Future applications may involve combining BCI with pharmacological treatments and rehabilitation training to create comprehensive, personalized therapy protocols [9] Market Dynamics - The increasing number of companies entering the BCI market is indicative of the industry's maturation, presenting both challenges and opportunities for established players [10] - The lack of industry standards and compliance issues may pose risks, but companies with strong technical foundations and regulatory adherence are likely to gain competitive advantages [10] - The focus on developing affordable, effective non-invasive products is crucial for expanding the market reach and achieving the vision of a healthier society [8]

Group 1 - A Hubei-based company has developed and received the first Class III medical device registration certificate for a transcranial magnetic stimulation (TMS) device in the mental health field in China [1][5] - The TMS technology is a non-invasive treatment method that stimulates brain neurons using magnetic fields, which can be beneficial for conditions such as depression [5][6] - The Chinese brain-computer interface (BCI) market is projected to reach 3.2 billion yuan in 2024, with an 18.8% year-on-year growth, and is expected to grow to 5.58 billion yuan by 2027, with a growth rate of 20% [6] Group 2 - The TMS technology is recognized as one of the four major brain science technologies of the 21st century, alongside PET, fMRI, and magnetoencephalography [5] - Hubei has emerged as a leader in the brain science sector, with several companies like Yirui, Zhonghua Brain Machine, and Green Tech making significant advancements [6] - The conference also showcased other innovations in brain science, including the Ami 3S navigation robot and the T-FUS technology [5]